Zhong Bin, Ma Dan-Dan, Zhang Tao, Gong Qi, Dong Yi, Zhang Jian-Xin, Li Zhong-Hu, Jin Wei-Dong
The First School of Clinical Medicine, Southern Medical University, Guangzhou, 510515, China.
Department of General Surgery, General Hospital of Central Theater Command, Wuhan, 430070, China.
Comb Chem High Throughput Screen. 2024;27(7):1011-1021. doi: 10.2174/1386207326666230810142646.
Pancreatic adenocarcinoma (PAAD) is a frequent malignant tumor with a high mortality rate. Searching for novel biomarkers that can influence its prognosis may help patients. It has been shown that tropomodulin-3 (TMOD3) may influence tumor progression, but its role in pancreatic cancer is not clear. We aimed to explore the expression and prognostic value of TMOD3 in PAAD.
We used bioinformatics analysis to analyze the relationship between TMOD3 expression and clinicopathological features and prognosis and verified it with clinical data from tissue microarray. We also conducted in vitro cell experiments to explore the effects of TMOD3 on the function of PAAD cells.
TMOD3 expression was found to be significantly higher in PAAD tissues than in matched paracancerous tissues (P < 0.05). Meanwhile, high TMOD3 expression was associated with significantly poorer overall survival (P < 0.05). Analysis of relevant clinicopathological characteristics data obtained from TCGA showed that high TMOD3 expression correlated with age, TNM stage, N stage, and M stage (P < 0.05). Analysis of correlation data obtained from tissue microarrays showed that high TMOD3 expression was associated with lymph node invasion, nerve invasion, macrovascular invasion, and TNM stage (P < 0.05). In addition, siRNA knockdown of TMOD3 significantly reduced the migration and invasion of PAAD cells.
Our study shows that TMOD3 may be associated with the progression of PAAD cells, and that it is an independent risk factor for poor pathological features and prognosis of PAAD. It may be helpful as a prognostic indicator of clinical outcomes in PAAD patients.
胰腺腺癌(PAAD)是一种常见的恶性肿瘤,死亡率很高。寻找能够影响其预后的新型生物标志物可能会对患者有所帮助。已有研究表明,原肌球蛋白3(TMOD3)可能影响肿瘤进展,但其在胰腺癌中的作用尚不清楚。我们旨在探讨TMOD3在PAAD中的表达及预后价值。
我们使用生物信息学分析来分析TMOD3表达与临床病理特征及预后之间的关系,并通过组织芯片的临床数据进行验证。我们还进行了体外细胞实验,以探讨TMOD3对PAAD细胞功能的影响。
发现PAAD组织中TMOD3的表达明显高于配对的癌旁组织(P < 0.05)。同时,TMOD3高表达与总体生存率显著较差相关(P < 0.05)。对从TCGA获得的相关临床病理特征数据的分析表明,TMOD3高表达与年龄、TNM分期、N分期和M分期相关(P < 0.05)。对从组织芯片获得的相关数据的分析表明,TMOD3高表达与淋巴结浸润、神经浸润、大血管浸润和TNM分期相关(P < 0.05)。此外,TMOD3的siRNA敲低显著降低了PAAD细胞的迁移和侵袭能力。
我们的研究表明,TMOD3可能与PAAD细胞的进展有关,并且它是PAAD病理特征差和预后不良的独立危险因素。它可能有助于作为PAAD患者临床结局的预后指标。